Cellectis S.A. (CMVLF)

Market Cap	235.00M +142.3%
Revenue (ttm)	79.59M +61.7%
Net Income	-67.59M
EPS	-0.67
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Average Volume	428
Open	4.400
Previous Close	4.500
Day's Range	4.400 - 4.400
52-Week Range	1.250 - 5.040
Beta	2.85
RSI	62.01
Earnings Date	Mar 19, 2026

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 219
• Stock Exchange: OTCMKTS
• Ticker Symbol: CMVLF

Financial Performance

In 2025, Cellectis's revenue was $79.59 million, an increase of 61.72% compared to the previous year's $49.22 million. Losses were -$67.59 million, 83.9% more than in 2024.